dc.contributor
Institut Català de la Salut
dc.contributor
[Takekuma M] Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan. [Nishio S] Department of Obstetrics and Gynecology, Kurume University Hospital, Kurume, Japan. [Yamaguchi S] Department of Gynecology, Hyogo Cancer Center, Akashi, Japan. [Yunokawa M] Department of Gynecology, Cancer Institute Hospital of JFCR, Tokyo, Japan. [Nishio H] Department of Obstetrics and Gynecology, Keio University Hospital, Tokyo, Japan. [Nishino K] Department of Obstetrics and Gynecology, Niigata University Medical & Dental Hospital, Niigata, Japan. [Villacampa G] Oncology Data Science, Vall d’Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d’Hebron Institut d'Oncologia (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Takekuma, Munetaka
dc.contributor.author
Nishio, Shin
dc.contributor.author
Yamaguchi, Satoshi
dc.contributor.author
Yunokawa, Mayu
dc.contributor.author
Nishio, Hiroshi
dc.contributor.author
Nishino, Koji
dc.contributor.author
Villacampa Javierre, Guillermo
dc.contributor.author
OAKNIN, ANA
dc.date.accessioned
2025-11-26T03:13:52Z
dc.date.available
2025-11-26T03:13:52Z
dc.date.issued
2025-11-24T10:31:42Z
dc.date.issued
2025-11-24T10:31:42Z
dc.identifier
Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, et al. Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. J Gynecol Oncol. 2025 Nov;36(6):e116.
dc.identifier
http://hdl.handle.net/11351/14090
dc.identifier
10.3802/jgo.2025.36.e116
dc.identifier.uri
http://hdl.handle.net/11351/14090
dc.description.abstract
Angiogenesis Inhibitors; Atezolizumab; Bevacizumab
dc.description.abstract
Inhibidores de la angiogénesis; Atezolizumab; Bevacizumab
dc.description.abstract
Inhibidors de l'angiogènesi; Atezolizumab; Bevacizumab
dc.description.abstract
Objective: This study analyzed the efficacy of add-on atezolizumab to standard first-line bevacizumab-containing therapy in 56 Japanese patients with metastatic and recurrent cervical cancer treated across 8 sites under the Japanese Gynecologic Oncology Group between October 2018 and August 2021 in the BEATcc trial.
Methods: Patients were randomized to standard arm (standard therapy: cisplatin 50 mg/m² or carboplatin area under the curve of 5, paclitaxel 175 mg/m², and bevacizumab 15 mg/kg) or experimental arm (standard therapy with atezolizumab 1,200 mg).
Results: Of 56 patients, 30 were in experimental arm vs. 26, standard arm (age: 53.2±12.9 vs. 54.7±12.2 years). Median progression-free survival was 15.8 months (95% confidence interval [CI]=10.4-26.1) in experimental arm vs. 11.1 months (8.4-16.5) in standard arm (hazard ratio [HR]=0.51; 95% CI=0.26-1.01). Median overall survival was 34.1 months (23.2-38.6) in the experimental arm vs. 31.6 months (16.4-36.5), standard arm (HR=0.53; 95% CI=0.23-1.21). Objective response rate was 86.7% in experimental arm vs. 84.6%, standard arm. Complete response and partial response, respectively, were 23.3% and 63.3% in experimental arm and 26.9% and 57.7% in standard arm. Grade ≥3 adverse events occurred in 80.0%, experimental arm and 88.5%, standard arm. Gastrointestinal/genitourinary fistula incidence was lower in Japanese patients (1 patient receiving atezolizumab), likely due to stricter inclusion criteria.
Conclusion: Overall, add-on atezolizumab enhances the efficacy of bevacizumab and chemotherapy in Japanese patients as those in overall BEATcc population and could be considered a new first-line treatment option for metastatic, persistent, or recurrent cervical cancer in Japan.
Trial registration: ClinicalTrials.gov Identifier: NCT03556839.
dc.description.abstract
The trial was funded by F. Hoffmann-La Roche AG and Chugai Pharmaceutical Co., Ltd.
dc.format
application/pdf
dc.publisher
Korean Society of Gynecologic Oncology
dc.relation
Journal of Gynecologic Oncology;36(6)
dc.relation
https://doi.org/10.3802/jgo.2025.36.e116
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
Quimioteràpia combinada
dc.subject
Coll uterí - Càncer - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
CHEMICALS AND DRUGS::Inorganic Chemicals::Platinum Compounds
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::compuestos de platino
dc.title
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
